Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources — Clinical Trial Site

39 Registered trials

17 Currently recruiting

Organisation

Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources

Location

Mont-De-Marsan Cedex, France

Identifier

ORG-100042615

Address

Avenue Pierre De Coubertin, Bp 417, 40024, France

Departments

gastro enterology
Gynecologie
hématologie
Hematology
Hematology unit
hépato gastro enterology
Hepato-gastroenterology
Hepatogastroenterology
Maladies Infectieuses
Maladies Infectieuses et Tropicales
Médecine Ambulatoire Oncologie
Médecine Interne
medical oncology
Multipurpose intensive care
Nephrology
Neurology
Oncologie
Oncologie Hématologie
Oncologie médicale
oncology
Pédiatrie
Pedriatrie
Service d'hématologie
Service d'hématologie clinique
Service de Pneumologie
Surgery

Clinical trials at this site (39)

Search interface

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Philadelphia-negative myeloproliferative neoplasms are 10
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Patients with previously untreated symptomatic chronic 4
Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) 5
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting

2024-516394-78-00 Patient with sepsis complicated by ARDS 5 2024-11-05
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting

2024-513219-29-00 Renal Cell Carcinoma 5 2024-10-21
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 patients with a positive status for molecular residual 5 2024-09-26
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre… Recruiting

2024-514952-34-00 Catheter related bloodstream infections due to Staphylo 5 2023-06-23
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
Preventive effect of Clopidogrel on the systemic sclerosis development risk Recruiting

2024-511005-39-00 Raynaud phenomenon 10 2022-06-22
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of… Ended

2024-517099-39-00 Newly diagnosed transplant ineligible multiple myeloma 4 2024-11-18
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 9 2023-12-06
Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended

2024-514878-53-00 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk in 4 2023-10-04